Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06928818
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
100 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Cancer of Breast


Trastuzumab Emtansine


Trastuzumab Deruxtecan
NOT_YET_RECRUITING
NCT07543536
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
132 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Advanced/Metastatic Breast Cancer


HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
ACTIVE_NOT_RECRUITING
NCT06731803
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
36 Enrollment(s)
15 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Esophagogastric Adenocarcinoma
ACTIVE_NOT_RECRUITING
NCT05480384
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
1 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE2)
Esophageal Adenocarcinoma


Esophageal Cancer


HER-2 Protein Overexpression


Gastroesophageal-junction Cancer
RECRUITING
NCT07340164
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
116 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Ovarian Cancer


Ovarian Carcinoma, Recurrent


Ovarian Cancer Metastatic Recurrent


Ovarian Cancer (OvCa)
TERMINATED
NCT04593784
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
41 Enrollment(s)
3 Study location(s)
INTERVENTIONAL (PHASE2)
Healthy
RECRUITING
NCT07537673
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan
25 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Nausea and Vomiting Caused by Trastuzumab Deruxtecan
RECRUITING
NCT06467357
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
620 Enrollment(s)
266 Study location(s)
INTERVENTIONAL (PHASE3)
Biliary Tract Cancer